UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,634	04/25/2005	Nicholas David Peter Cosford	MS0013YP	9423
210 MERCK AND	7590 03/18/200 CO., INC	EXAMINER		
PO BOX 2000			MORRIS, PATRICIA L	
RAHWAY, NJ 07065-0907			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			03/18/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/532,634	COSFORD ET AL.
Office Action Summary	Examiner	Art Unit
	David K. O'Dell	1625
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO .136(a). In no event, however, may a reply be tin I will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	N. mely filed I the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 25 A This action is FINAL . 2b) ☑ This Since this application is in condition for allowed closed in accordance with the practice under	s action is non-final. ance except for formal matters, pr	
Disposition of Claims		
4) Claim(s) <u>1-22</u> is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-22</u> are subject to restriction and/or	awn from consideration.	
Application Papers		
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat* See the attached detailed Office action for a list	nts have been received. Its have been received in Applicat prity documents have been receiv au (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	ate

Application/Control Number: 10/532,634

Art Unit: 1625

DETAILED ACTION

Page 2

1. This application is a 371 of PCT/US03/33613, filed 10/24/2003, and claims priority from provisional application 60/420809 filed 10/24/2002.

Claims 1-22 are pending.

2. Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, Claims 1-11, 20 drawn to compounds and compositions reading on claim 1, where A is thiazole and B is phenyl drawn to 1-thiazolyl-2-phenyl-ethynes. If this group is elected, a further election of a single disclosed species is also required. Further restriction based on the election may be made.

Group II, Claims 1-11, drawn to compounds and compositions reading on claim 1, where A is thiazole and B is pyridyl drawn to 1-thiazolyl-2-pyridyl-ethynes. If this group is elected, a further election of a single disclosed species is also required. Further restriction based on the election may be made.

Group III, Claims 1-11 drawn to compounds and compositions reading on claim 1, where A is pyridyl and B is phenyl drawn to 1-phenyl-2-pyridyl-ethynes. If this group is elected, a further election of a single disclosed species is also required. Further restriction based on the election may be made.

Group IV, Claims 1-11 drawn to compounds and compositions reading on claim 1, where A is pyridyl and B is pyridyl drawn to 1,2-dipyridyl-ethynes. If this group is elected, a further election of a single disclosed species is also required. Further restriction based on the election may be made.

Group V, Claims 1-11 drawn to compounds and compositions not encompassed by groups I-IV. If this group is elected, a further election of a single disclosed species is also required. Further restriction based on the election may be made.

Group VI, Claim 12, drawn to methods of making the compounds of Groups I-V, limited in scope to one of the groups I-V. If this group is elected, a further election of a compound groups

Application/Control Number: 10/532,634 Page 3

Art Unit: 1625

and a single disclosed species is also required. In addition a further election of a "precursor" and all the "steps of reacting" is required. Further restriction based on the species election will be required.

Group VII, Claims 12-19, 21 drawn to methods of using the compounds of Groups I-V in PET scans, limited in scope to one of the groups I-V. If this group is elected, a further election of a compound groups and a single disclosed species is also required. In addition a further election of a "disorder" is required. Further restriction based on the species election may be required.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under 35 USC 121 or PCT Rule 13.1 because:

PCT Rule 13.1 states that the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention").

PCT Rule 13.2 states that the unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features.

Annex B, Part 1(a), indicates that the application should relate to only one invention, of if there is more than one invention, inclusion is permitted if they are so slinked to form a single general inventive concept.

Annex B Part 1(b), indicates that "special technical features" means those technical features that as a whole define a contribution over the prior art.

Annex B Part 1(c), further defines independent and dependent claims. Unity of invention only is concerned in relation to independent claims. Dependent claims are defined as a claim that contains all the features of another claim and is in the same category as the other claim. The category of a claim refers to the classification of claims according to subject matter e.g. product, process, use, apparatus, means, etc.

Annex B Part 1(e), indicates that the permissible combinations of different categories of claims. Part 1(e)I, states that inclusion of an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of the said product, and an independent claim for a use of the said product is permissible.

Annex B, Part 1(f), indicates the "Markush practice" of alternatives in a single claim. Part 1(f)I, indicates the technical relationship and the same or corresponding special technical feature is considered to be met when (A) all alternatives have a common property or activity, and (B) a common structure is present or all alternatives belong to a recognized class of chemical compounds. Further defining (B), Annex B, Part 1(f)(i-iii), the common structure must; a) occupy a large portion of their structure, or b) the common structure constitutes a structurally distinctive portion, or c) where the structures are equivalent and therefore a recognized class of chemical compounds, each member could be substituted for one another with the same intended result. That is, with a common or equivalent structure, there is an expectation relationship and the corresponding special technical feature result from a common (or equivalent) structure that is responsible for the common activity (or property). Part 1(f) iv, indicates that when all

Application/Control Number: 10/532,634

Art Unit: 1625

alternatives of a Markush grouping can be differently classified, it shall no, take alone, be considered justification for finding a lack of unity. Part 1(f)v, indicates that

"When dealing with alternatives, if it can be shown that at least *one* Markush alternative is not novel over the prior art, the question of unity of invention shall be reconsidered by the examiner"

In the instant case, at least one Markush alternative is not novel because prior art by Bohlmann, Ferdinand et. al. "Polyacetylenic compounds. LXXII. Biogenetic conversions of tridecenepentayne." *Chemische Berichte*, **1965**, 98, 876-82 (abstract only) recites a compound of the instant case

```
RN 1213-30-5 CAPLUS
CN Thiophene, 2-(3,4-epoxy-1-butynyl-3,4-t2)-5-(1,3-pentadiynyl)- (7CI, 8CI)
(CA INDEX NAME)

C=C-C=C-Me
```

, thus the lack of a special technical feature is apparent.

Inventions I-V and VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case at least the method of PET imaging (claim 13) can be practiced with fluoro-deoxyglucose.

Inventions I-V and VI are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the compound Bohlman et. al., may be prepared by the non-standard synthetic procedures described in the reference above (supra).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn and the rejoined process claims will be fully

Page 5

examined for patentability in accordance with 37 CFR 1.104. Thus, to be **allowable**, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai; In re Brouwer and 35 U.S.C.§ 103(b)," 1184 O.G. 86 (March 26, 1996).

Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include all the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01. Filing of appropriate terminal disclaimer in anticipation of a rejoinder may speed prosecution and the process of rejoinder.

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species and invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/532,634 Page 6

Art Unit: 1625

Any inquiry concerning this communication should be directed to JANET L. ANDRES at telephone number (571)272-0867.

/JANET L ANDRES/ Supervisory Patent Examiner, Art Unit 1625